You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's diagnostics, diagnostics excluding blood, and breast health divisions are all anticipated to post healthy year-over-year improvements.
The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Chembio's Q3 revenues are expected to rise between 21 and almost 24 percent year over year. It is purchasing OpTricon, which develops handheld analyzers, for $5.5 million.
NanoString Technologies hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
LabCorp Diagnostics revenues increased 9 percent in Q4, while Covance Drug Development grew revenues 24 percent.
The company also announced that its Ares Genetics subsidiary has been awarded a €1.6 million grant to develop antibiotic resistance technologies.
Abbott's CFO said he expects mid-single-digit growth from diagnostics in Q1 2018 and mid-to-high single digit growth for the full year.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
The firm expects full-year revenue of between $103 and $103.5 million, compared to a prior guidance of $103.5 to $104.5 million.
Invitae is expecting to net revenues of $59 million in 2017 via its base business, and $67 million in total revenues including acquired companies.